Erasca (ERAS) Total Non-Current Liabilities (2020 - 2026)
Erasca posted quarterly Total Non-Current Liabilities of $67.4 million for Q1 2026, down 5.77% year-on-year from $71.5 million in Q1 2025, and down 4.56% on a QoQ basis from $70.6 million in Q4 2025.
Erasca (ERAS) has 7 years of Total Non-Current Liabilities data on file, last reported at $67.4 million in Q1 2026.
- For the quarter ending Q1 2026, Total Non-Current Liabilities fell 5.77% year-over-year to $67.4 million; the trailing twelve-month figure through Mar 2026 stood at $67.4 million (down 5.77% YoY), and the FY2025 full-year result was $70.6 million, down 10.27% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $67.4 million, down from $70.6 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $102.5 million in Q4 2022 and bottomed at $67.4 million in Q1 2026.
- The 5-year median for Total Non-Current Liabilities is $77.7 million (2023), against an average of $77.5 million.
- The widest annual swing landed in 2022, when Total Non-Current Liabilities surged 129.12%; it then decreased 23.85% in 2023.
- A 5-year view of Total Non-Current Liabilities shows it stood at $102.5 million in 2022, then retreated by 23.85% to $78.0 million in 2023, then rose by 0.79% to $78.7 million in 2024, then declined by 10.27% to $70.6 million in 2025, then decreased by 4.56% to $67.4 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $67.4 million (Q1 2026), $70.6 million (Q4 2025), and $72.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 11.03 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 42,980.09 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 95.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 110.28 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.87 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 7.32 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Erasca | 4.21 Bn | 3.97 Bn | - | 67.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 67.37 Mn |
| Dec 31, 2025 | 70.58 Mn |
| Sep 30, 2025 | 72.12 Mn |
| Jun 30, 2025 | 72.87 Mn |
| Mar 31, 2025 | 71.49 Mn |
| Dec 31, 2024 | 78.67 Mn |
| Sep 30, 2024 | 78.51 Mn |
| Jun 30, 2024 | 74.58 Mn |
| Mar 31, 2024 | 81.05 Mn |
| Dec 31, 2023 | 78.05 Mn |
| Sep 30, 2023 | 79.67 Mn |
| Jun 30, 2023 | 77.26 Mn |
| Mar 31, 2023 | 80.46 Mn |
| Dec 31, 2022 | 102.48 Mn |
| Dec 31, 2021 | 44.73 Mn |
| Dec 31, 2020 | 15.79 Mn |